A New CT-Based Plaque Score Predicts Stroke Risk Better Than Artery Narrowing Alone

Table of Contents

• Key Points
• Why This Research Matters: Carotid Artery Disease and Stroke
• How the Study Was Conducted
• Who Was Studied
• Key Finding: High-Risk Plaques and Stroke Symptoms
• Better Prediction Than Artery Narrowing Alone
• Long-Term Outcomes: First Strokes and Recurrences
• Are the Readings Reliable?
• What This Means for Patients
• Limitations of This Study
• Recommendations Based on This Research
• Frequently Asked Questions
• Source Information

Key Points

• In a study of 1,232 patients, a CTA-based plaque score called Plaque-RADS predicted first and recurrent strokes better than artery narrowing alone.
• High-risk plaque features (Plaque-RADS 3 or higher) predicted worse outcomes even in patients with only mild-to-moderate narrowing (less than 70%).
• Among patients with severe stenosis, carotid revascularization was associated with an 83% relative reduction in recurrence risk, with no peri-procedural strokes observed.
• The study was retrospective and single-center; prospective validation is needed before Plaque-RADS becomes a universal standard.

Why This Research Matters: Carotid Artery Disease and Stroke

Ischemic stroke is a major subtype of cerebrovascular disease. It makes up approximately 85% of all stroke cases and remains one of the leading causes of death and long-term disability worldwide. Most of these strokes happen when a blood clot or plaque fragment travels from the carotid artery to the brain, blocking blood flow.

Atherosclerotic disease of the carotid artery — particularly at the carotid bifurcation (where the common carotid artery splits into branches) and the internal carotid artery — plays a critical role in causing anterior circulation ischemic events. Anterior circulation refers to the blood vessels that supply the front and middle parts of the brain, which control movement, sensation, and language.

Traditionally, doctors have used the severity of luminal stenosis (the percentage of artery narrowing) as the primary imaging biomarker for risk stratification and treatment decisions. However, growing evidence shows that stenosis severity alone is not the most accurate predictor of plaque stability, vulnerability, or the occurrence of cerebrovascular events. A plaque that causes only mild narrowing can still rupture and cause a stroke, while a severely narrowed artery can sometimes remain stable for years.

In recent years, carotid plaque imaging has significantly advanced stroke risk stratification. Specific imaging biomarkers of vulnerable plaques — meaning plaques that are prone to rupture — include intraplaque hemorrhage (IPH, bleeding inside the plaque), fibrous cap rupture (tearing of the protective tissue covering the plaque), and contrast enhancement. These features have been shown to play critical roles in guiding clinical decisions and individualized treatment strategies.

Several technique-specific scoring systems already exist. These include the American Heart Association histologic classification, a modified American Heart Association classification for MRI, and carotid plaque scoring on ultrasound. Inconsistent interpretation across imaging techniques has limited their clinical usefulness in practice.

To address the need for a standardized framework, the carotid Plaque Reporting and Data System (Plaque-RADS) was recently introduced. This classification system integrates imaging features across multiple modalities — ultrasound, MRI, and CTA — to stratify plaques from Plaque-RADS 1 (no atherosclerosis) to Plaque-RADS 4 (plaques with complex, high-risk characteristics). While the multimodal design improves theoretical accuracy, certain high-risk features like fibrous cap rupture are best seen with MRI vessel wall imaging. That limitation restricts the system's broad use in everyday clinical settings.

CTA, one of the most widely used imaging tests for carotid artery disease, offers high spatial resolution and short acquisition times. It can show the degree of luminal stenosis and also detect plaque features such as calcification, ulceration (an open crater in the plaque surface), and intraluminal thrombus (a blood clot inside the artery). A CTA-based version of Plaque-RADS has been proposed, but its independent predictive value for ischemic cerebrovascular events (ICE) — a term that includes both strokes and transient ischemic attacks — had not been systematically validated in a large, real-world population. This study set out to do exactly that.

How the Study Was Conducted

This was a retrospective study, meaning researchers looked back at medical records and previously taken scans. It was approved by the Medical Ethics Committee of Nanfang Hospital (approval number NFEC-2022-168), and the requirement for written informed consent was waived because the study used existing data. The researchers followed the STROBE guidelines, an international standard for reporting observational studies.

The researchers retrieved imaging and clinical data for 7,228 patients who underwent neck CTA between January 2019 and March 2024, using the hospital's PACS (Picture Archiving and Communication System). Eligible adults were 18 years of age or older and either had ischemic events in the carotid territory or were asymptomatic (free of symptoms) individuals undergoing CTA.

Key exclusion criteria included:

• Atrial fibrillation or documented cardioembolic sources (blood clots originating from the heart)
• Prior carotid revascularization (a previous procedure to reopen the artery)
• Internal carotid artery occlusion (complete blockage)
• CTA performed more than 30 days after a stroke
• Poor image quality
• Malignancy or neck irradiation (radiation treatment to the neck)

Patients were classified as symptomatic or asymptomatic. Symptomatic patients had carotid-territory ischemia, including transient ischemic attack (TIA, a "mini-stroke" with focal neurologic symptoms resolving within 24 hours) or acute ischemic stroke (a new focal neurologic deficit lasting more than 24 hours and/or MRI evidence of acute infarction). Asymptomatic individuals had no history of TIA or ischemic stroke at or before their baseline CTA. In this cohort, neck CTA was most commonly requested for preoperative risk assessment or carotid screening.

A total of 1,232 eligible patients were identified: 458 symptomatic and 774 asymptomatic. Because symptomatic and asymptomatic groups can differ in ways that skew results, the researchers used propensity score matching (PSM, a statistical technique that pairs similar patients to balance groups). Using 1:1 nearest-neighbor matching with a caliper of 0.01 and matching on sex, hypertension, hyperlipidemia, diabetes, and smoking, they created 371 matched pairs (742 patients total) for analysis.

Two radiologists with more than 5 years of experience independently reviewed all anonymized images. They were blinded to symptomatic status, outcomes, stenosis measurements, and clinical variables. Any discrepancies were resolved by a senior reader with more than 30 years of experience. Before starting, the readers jointly reviewed representative cases and Plaque-RADS definitions to standardize their scoring criteria.

For each patient, both carotid arteries were assessed. A plaque was defined as focal wall thickening of at least 1.5 mm, measured at the distal common carotid bifurcation, carotid bulb, and proximal internal carotid artery. Purely calcified lesions within these segments were also counted as plaque. Maximum wall thickness (MWT) was the greatest wall or plaque thickness measured. Intraplaque hemorrhage required a region of interest of more than 2 mm² with a density of less than 25 Hounsfield units (HU, the scale used to measure tissue density on CT). Ulceration was defined as contrast outpouching of at least 1 mm. Intraluminal thrombus was defined as a filling defect surrounded by contrast.

The CTA-based Plaque-RADS categories used in this study were:

1. Plaque-RADS 1: normal wall
2. Plaque-RADS 2: maximum wall thickness less than 3 mm
3. Plaque-RADS 3: maximum wall thickness of 3 mm or more
4. Plaque-RADS 3c: ulcerated plaque
5. Plaque-RADS 4a: intraplaque hemorrhage (bleeding within the plaque)
6. Plaque-RADS 4c: intraluminal thrombus (blood clot in the artery)

Stenosis was calculated according to the NASCET (North American Symptomatic Carotid Endarterectomy Trial) criteria, a standard method for measuring carotid narrowing. It was graded as mild (less than 50% narrowing), moderate (50%–69%), or severe (70%–99%).

After propensity score matching, 742 patients were followed from the date of their CTA to ischemic stroke, recurrence, death, or the study end in March 2024. Follow-up was conducted through medical records or structured telephone interviews. The primary endpoint was ischemic stroke (first or recurrent); the secondary endpoint was all-cause mortality. Events were confirmed by diffusion-weighted MRI (a scan that detects recent brain damage) when available. When MRI was unavailable, events were adjudicated based on persistent focal neurologic deficits documented by stroke neurologists or obtained through a structured telephone questionnaire that systematically asked about new focal neurologic deficits, symptom onset, duration, and related hospitalizations and brain imaging.

Statistical analyses were performed using RStudio (Version 4.0.3) and GraphPad Prism (Version 10.0). Missing data for cholesterol measurements were handled using multiple imputation by chained equations, generating 20 imputed datasets. The researchers used a range of powerful statistical tools, including logistic regression with generalized estimating equations (GEE, which accounts for the fact that each patient contributed two carotid arteries), receiver operating characteristic (ROC) curves to measure diagnostic accuracy, the DeLong test to compare models, Cox proportional hazards models for time-to-event analysis, and Kaplan-Meier survival curves to visualize outcomes over time. Inter- and intraobserver agreement was assessed using a weighted kappa (κ) statistic.

Who Was Studied

After propensity score matching, the symptomatic and asymptomatic groups were well balanced on key characteristics. Before matching, the symptomatic group had higher proportions of males, smokers, and people with hypertension, hyperlipidemia, and diabetes (P < .05). After matching, these differences disappeared.

Baseline characteristics after matching included:

• Median age: 66 years (interquartile range 59–71) in asymptomatic individuals vs. 64 years (56–71) in symptomatic patients (P = .15)
• Male sex: 46.9% in both groups
• Hypertension: 61.5% in both groups
• Hyperlipidemia (high blood fats): 28.0% in both groups
• Diabetes: 31.0% vs. 34.2% (P = .35)
• Coronary artery disease: 11.1% vs. 7.3% (P = .08)
• Smoking history: 27.5% in both groups
• Statin use: 5.9% vs. 6.2% (P = .88)
• Total cholesterol: 4.96 vs. 4.71 mmol/L (P = .08)
• HDL-C ("good" cholesterol): 1.13 vs. 1.14 mmol/L (P = .90)
• LDL-C ("bad" cholesterol): 3.11 vs. 3.01 mmol/L (P = .11)

Plaque-RADS categories, stenosis degree, and stenosis percentage differed significantly between asymptomatic and symptomatic plaques (P < .001). Higher-grade plaques (categories 3, 3c, 4a, and 4c) were more frequent in symptomatic cases, while grades 1–2 predominated in asymptomatic cases. Symptomatic plaques also showed higher stenosis severity and percentage.

An exploratory analysis of plaque laterality found right-sided intraplaque hemorrhage in 66 of 742 patients (8.9%), with no significant association with symptom status (odds ratio [OR] 1.31; 95% confidence interval [CI] 0.79–2.19; P = .30). Right-sided 4a plaques (intraplaque hemorrhage) had a lower symptomatic rate than left-sided 4a and 3c plaques, but the small number of events makes this finding uncertain.

Key Finding: High-Risk Plaques and Stroke Symptoms

The researchers found a modest positive association between Plaque-RADS category and ischemic cerebrovascular events. The Kendall tau-b correlation coefficient was 0.23 (95% CI, 0.18–0.27; P < .001). In plain terms, higher Plaque-RADS categories were significantly linked to having had a stroke or TIA. A "modest" correlation means the relationship is real but not perfect — plaque features are not the only factor determining stroke risk.

In plaque-level models using generalized estimating equations, the higher-risk categories (3c, 4a, and 4c) were strongly associated with symptomatic plaques. Notably, stenosis degree itself was not independently associated with symptomatic status once Plaque-RADS and clinical variables were taken into account. This is a striking finding: it suggests that what the plaque looks like matters more than how much it narrows the artery.

Better Prediction Than Artery Narrowing Alone

To compare the diagnostic performance of Plaque-RADS against the traditional approach, the researchers built two statistical models. The base model used stenosis degree plus clinical covariates (age, sex, hypertension, and other risk factors). The second model added Plaque-RADS to that base.

The results were clearly in favor of adding Plaque-RADS:

• Base model (stenosis + clinical factors): area under the curve (AUC) of 0.609 (95% CI, 0.577–0.641)
• Model with Plaque-RADS added: AUC of 0.680 (95% CI, 0.649–0.711)
• The difference (ΔAUC) was 0.07, which was statistically significant (DeLong P < .001)

The AUC is a measure of how well a test distinguishes between people who will have an event and those who will not. An AUC of 0.5 means the test is no better than a coin flip; 1.0 means perfect prediction. The improvement from 0.609 to 0.680 represents a meaningful gain in predictive accuracy. The P value of less than .001 means there is less than a 0.1% chance this improvement occurred by random chance.

The Plaque-RADS-augmented model demonstrated good calibration, meaning its predicted risks closely matched actual outcomes. Decision curve analysis also showed that the model provided a higher standardized net benefit than "treat all" or "treat none" strategies for threshold probabilities of 10%–30%. In everyday terms, this means using Plaque-RADS helps doctors make better treatment decisions across a clinically relevant range of risk levels.

Long-Term Outcomes: First Strokes and Recurrences

During a mean follow-up of 42 months (standard deviation 18 months), ischemic stroke occurred in 27 of 371 asymptomatic individuals (7.3%, about 7 in 100) and in 65 of 371 symptomatic patients (17.5%, about 18 in 100). Of these events, 33.3% in the asymptomatic cohort and 50.2% in the symptomatic cohort were confirmed by MRI; the remainder were diagnosed clinically or confirmed through interviews.

The researchers tracked two types of outcomes. Disease-free survival (DFS) measured the time until a first stroke in asymptomatic people. Recurrence-free survival (RFS) measured the time until a repeat stroke in symptomatic patients.

First strokes (asymptomatic patients):

• Plaque-RADS 1: 0 of 67 patients had a stroke (0%). The 3-year DFS rate was 100.0%, and the 5-year rate was 100.0%.
• Plaque-RADS 2: 8 of 159 patients (5.0%, about 1 in 20). The 3-year DFS rate was 97.2%, and the 5-year rate was 91.0%.
• Plaque-RADS 3: 9 of 82 patients (11.0%, about 1 in 9). The 3-year DFS rate was 94.2%, and the 5-year rate was 83.3%.
• Plaque-RADS 4: 10 of 63 patients (15.9%, about 1 in 6). The 3-year DFS rate was 82.8%, and the 5-year rate was 72.5%.

Stroke incidence per person-year rose steadily from 0.00 for Plaque-RADS 1 to 0.05 for Plaque-RADS 4. The unadjusted hazard ratio (HR, a measure of how much more often events occur over time) for Plaque-RADS 4 compared with Plaque-RADS 1 was 21.93 (95% CI, 2.78–173.11). After adjusting for confounding factors, the HR remained high at 11.84 (95% CI, 1.27–110.32; P < .05).

Recurrent strokes (symptomatic patients):

• Plaque-RADS 1: 1 of 39 patients (2.6%, about 3 in 100). The 3-year RFS rate was 100.0%, and the 5-year rate was 95.2%.
• Plaque-RADS 2: 14 of 122 patients (11.5%, about 1 in 9). The 3-year RFS rate was 95.4%, and the 5-year rate was 86.4%.
• Plaque-RADS 3: 16 of 85 patients (18.8%, about 1 in 5). The 3-year RFS rate was 81.7%, and the 5-year rate was 79.8%.
• Plaque-RADS 4: 34 of 114 patients (29.8%, about 3 in 10). The 3-year RFS rate was 72.2%, and the 5-year rate was 65.0%.

Recurrence incidence per person-year climbed from 0.01 for Plaque-RADS 1 to 0.10 for Plaque-RADS 4. The multivariable-adjusted HR for Plaque-RADS 4 versus Plaque-RADS 1 was 8.91 (95% CI, 1.92–41.32; P < .05).

Two specific findings stood out in the survival analysis:

• In asymptomatic patients, Plaque-RADS ≥3 was associated with a higher hazard of first stroke (HR 3.16; 95% CI, 1.27–7.86; P = .01). Severe stenosis was also a significant predictor (HR 4.79; 95% CI, 1.30–17.62; P = .02).
• In symptomatic patients, Plaque-RADS ≥3 was associated with a higher hazard of recurrent stroke (HR 3.7; 95% CI, 2.07–6.79; P < .001). Severe stenosis also predicted recurrence (HR 3.30; 95% CI, 1.74–6.26; P < .001).

Kaplan-Meier curves showed stepwise declines in disease-free and recurrence-free survival with increasing Plaque-RADS categories. The most significant group differences were between Plaque-RADS 1 and Plaque-RADS ≥3 (P < .001). Severe stenosis was associated with significantly lower DFS and RFS compared with mild or moderate stenosis (P < .001).

One of the most clinically important findings involved patients with only mild-to-moderate stenosis (less than 70% narrowing). Within this group, Plaque-RADS ≥3 predicted significantly worse DFS and RFS (P < .001). This means the scoring system catches high-risk patients that the traditional stenosis-based approach would miss. Additionally, among patients with severe stenosis, carotid revascularization (a procedure such as endarterectomy or stent placement to reopen the artery) improved recurrence-free survival (P < .05). When carotid revascularization was modeled as a time-dependent covariate, it was associated with a lower risk of recurrence (HR 0.17; 95% CI, 0.05–0.60; P = .006), meaning about an 83% relative reduction in recurrence risk. No peri-procedural ischemic strokes were observed.

Are the Readings Reliable?

For any scoring system to be useful, different doctors must be able to apply it consistently. The study measured this directly. Interobserver agreement (how well two different radiologists agreed) was good, with a weighted kappa of 0.87. Intraobserver agreement (how consistently the same radiologist scored the same images) was excellent, with a weighted kappa of 0.92. This strong reproducibility supports the system's practical use in routine clinical workflows.

What This Means for Patients

Among all the Plaque-RADS categories, Plaque-RADS 4c (intraluminal thrombus) showed the strongest predictive value for ischemic events, with an odds ratio of 17.87 (95% CI, 6.09–52.42; P < .001). An odds ratio this high means patients with a visible clot in their carotid artery had an enormously higher chance of having experienced a stroke or TIA. This aligns with prior research. Up to 92% of carotid thrombi are associated with neurologic symptoms, and CTA is well suited to detect them.

The other high-risk categories also mattered. Plaque-RADS 3 (thick plaque), 3c (ulceration), and 4a (intraplaque hemorrhage) were each associated with higher risk of ischemic events. CTA detects ulceration with high sensitivity and specificity (87% and 99%, respectively). Previous studies have shown that ulceration or increased wall thickness on CTA correlates with recent ipsilateral ischemia — meaning reduced blood flow on the same side of the brain as the abnormal plaque.

The key takeaway for patients is this: the degree of narrowing in your carotid artery is only part of the story. Two patients can have the exact same percentage of stenosis, yet one may face a much higher stroke risk because of the type of plaque present. CTA-based Plaque-RADS captures those differences. The authors describe it as a practical, single-technique tool that can be integrated into routine workflows to flag high-risk patients for intensified monitoring or earlier treatment.

The finding that Plaque-RADS independently predicted both first and recurrent strokes in patients with mild-to-moderate stenosis is particularly important. Traditionally, these patients might be told their risk is low because their artery is not severely narrowed. This study suggests that a high-risk plaque appearance should prompt more attention even when the narrowing looks modest.

Limitations of This Study

This study has several limitations that should be kept in mind when interpreting the results:

• Retrospective design: Because the study looked back at existing data rather than following patients forward in a planned trial, it can show associations but cannot prove cause and effect.
• CTA cannot assess the fibrous cap: CTA cannot reliably evaluate the condition of the fibrous cap (the protective covering of the plaque), particularly for the Plaque-RADS 3b and 4b categories that rely on MRI. As a result, the reported values may be conservative — some plaques that actually had fibrous cap rupture or thinning may have been classified into the less severe Plaque-RADS 3 or even 2 categories. This could mean the true predictive power of the system is even stronger than reported.
• Small numbers at late follow-up: Because relatively few patients remained under observation at the 5-year mark, the tail estimates of the survival curves are provided descriptively and should be interpreted cautiously.
• Exploratory laterality finding: The observation that right-sided 4a plaques were less frequently associated with symptoms is based on a small number of events with wide confidence intervals and was not adjusted for multiple testing. It should be considered hypothesis-generating rather than conclusive.
• Single-center study: All patients came from one hospital in China, which may limit how broadly the results generalize to other populations and healthcare settings.
• Incomplete MRI confirmation: Only about one-third to one-half of stroke events were confirmed by MRI; the rest relied on clinical assessment, which is less definitive.

Recommendations Based on This Research

Based on this study's findings, here is what patients and their doctors may want to consider:

1. Ask about plaque features, not just the percentage of narrowing. If you have had a carotid CTA, ask whether your radiologist assessed plaque characteristics such as wall thickness, ulceration, intraplaque hemorrhage, or thrombus. These features can matter more than stenosis degree alone.
2. Pay attention to mild and moderate stenosis. If your carotid artery shows only mild-to-moderate narrowing (less than 70%), but imaging reveals high-risk plaque features (Plaque-RADS 3 or higher), your stroke risk may be higher than the stenosis percentage alone suggests. This study found such patients had significantly worse outcomes, and earlier intervention might be warranted.
3. Understand that clot detection is especially serious. The strongest predictor in this study was Plaque-RADS 4c, meaning an intraluminal thrombus (a visible blood clot in the artery). If your scan shows this, it warrants urgent attention.
4. Discuss revascularization options if you have severe stenosis. The study found that carotid revascularization (endarterectomy or stenting) was associated with an 83% relative reduction in recurrence risk (HR 0.17; P = .006), with no peri-procedural strokes observed in this cohort.
5. Control traditional risk factors. Hypertension, hyperlipidemia, diabetes, and smoking were all more common in symptomatic patients before matching. Managing these remains the foundation of stroke prevention, regardless of what a scan shows.
6. Expect more validation studies. The authors note that prospective validation of CTA-based Plaque-RADS is needed. Patients and clinicians should watch for future research confirming these findings before the system becomes a universal standard.

This research was supported by the National Natural Science Foundation of China (grants 82171929 and 32571282) and the Natural Science Foundation of Guangdong Province (grant 2024A1515011520).

Frequently Asked Questions

What is Plaque-RADS and how does it work?

Plaque-RADS is a scoring system that reads detailed plaque features from CT angiography (CTA) scans of the neck. It grades plaques from 1 (normal) to 4 (complex, high-risk), based on features like wall thickness, ulceration, intraplaque hemorrhage, and intraluminal thrombus. In a study of 1,232 patients, this CTA-based score predicted strokes better than measuring artery narrowing alone.

I have only mild narrowing in my carotid artery. Should I still worry?

Possibly. In a study of 1,232 patients, those with only mild-to-moderate narrowing (less than 70%) but high-risk plaque features (Plaque-RADS 3 or higher) had significantly worse outcomes. The degree of narrowing is only part of the story; plaque appearance can matter more. Ask your doctor whether your CTA report assessed plaque features, not just the percentage of stenosis.

What does Plaque-RADS 4c mean on my scan?

Plaque-RADS 4c means an intraluminal thrombus—a visible blood clot inside the carotid artery. In a study of 1,232 patients, this category had the strongest link to ischemic events, with an odds ratio of 17.87. If your scan shows this, it warrants urgent attention. Discuss with your doctor what monitoring or treatment is appropriate for your situation.

How accurate is CTA-based Plaque-RADS for predicting stroke?

In a study of 1,232 patients, adding Plaque-RADS to a model with stenosis and clinical factors improved prediction, raising the area under the curve from 0.609 to 0.680. This was statistically significant. The system also showed good reproducibility between radiologists. However, it is not perfect; plaque features are not the only factor determining stroke risk.

Can Plaque-RADS help decide if I need carotid surgery or stenting?

In a study of 1,232 patients, among those with severe stenosis, carotid revascularization (endarterectomy or stenting) was associated with an 83% relative reduction in recurrence risk. No peri-procedural strokes were observed. For patients with mild-to-moderate stenosis but high-risk plaques, the study suggests earlier intervention might be warranted. Discuss your individual case with your doctor.

What are the limitations of this Plaque-RADS study?

The study was retrospective, so it shows associations but cannot prove cause and effect. It was single-center, all patients came from one hospital in China, which may limit generalizability. CTA cannot assess the fibrous cap, so some high-risk plaques may have been classified as lower risk. Only about one-third to one-half of stroke events were confirmed by MRI. Prospective validation is needed.

What should I do if my CTA report only mentions the percentage of narrowing?

Ask your doctor whether the radiologist assessed plaque features such as wall thickness, ulceration, intraplaque hemorrhage, or thrombus. In a study of 1,232 patients, these features predicted stroke better than narrowing alone. If you have mild-to-moderate narrowing but high-risk plaque features, your risk may be higher than the percentage suggests. Discuss next steps with your healthcare provider.

My carotid CTA shows only mild-to-moderate narrowing but my doctor says I'm low risk — should I get a second opinion on my plaque features?

Yes, this is a reasonable situation to seek a second opinion. Narrowing alone is not the most accurate predictor of stroke risk: a plaque causing only mild-to-moderate narrowing (under 70%) can still rupture. In 1,232 patients followed about 42 months, Plaque-RADS 3 or higher predicted significantly worse first-stroke and recurrence outcomes even in mild-to-moderate stenosis, and CTA-based Plaque-RADS predicted stroke better than stenosis alone. An independent review can assess wall thickness, ulceration, intraplaque hemorrhage, or thrombus on your existing CTA images. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: CTA-Based Carotid Plaque Reporting and Data System Classification

Authors: Limei Deng, Weixiong Zeng, Jingjing Yang, Weixi Zhu, Jiayu Lai, Yuan Huang, Dongqin Lv, Zilong He, Yijun Lv, Genggeng Qin, and Weiguo Chen (Limei Deng and Weixiong Zeng contributed equally to this study).

Journal: AJNR American Journal of Neuroradiology, 2026, Volume 47, Issue 6, pages 1483–1491.

DOI: https://doi.org/10.3174/ajnr.A9139

Affiliation: Nanfang Hospital, Southern Medical University, Guangzhou, China, and collaborating institutions.

This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace individualized medical advice from your healthcare provider.